Lv51
871 积分 2021-05-10 加入
Bystander effect in antibody-drug conjugates: Navigating the fine line in tumor heterogeneity
4小时前
待确认
化疗相关腹泻全程管理中国专家共识(2025年版)
3个月前
已完结
Pancreatic cancer
3个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
4个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
4个月前
已完结
Exploring the next generation of antibody-drug conjugates
4个月前
已完结
Antibody-drug conjugates for cancer therapy
4个月前
已完结
Optimal two-stage designs for phase II clinical trials
4个月前
已完结
Admissible two-stage designs for phase II cancer clinical trials
4个月前
已完结
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
5个月前
已关闭
皖公网安备34019202002308
